lambda-Cyhalothrin, (-)-


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:20097460IVTH0.000000001 - 0.00001 M 0.0000001 MOccurrence of mammary gland tumorEndocrine-mediated cancer;Reproductive endocrine-mediated perturbations
IVTH0.000000001 - 0.00001 M 0.0000001 MCancer phenotypeEndocrine-mediated cancer
PMID:29506456IVR6.3 mg/kg 6.3 mg/kgAffects steroidogenesisReproductive endocrine-mediated perturbations
IVR6.3 mg/kg 6.3 mg/kgDecreased cholesterol levelsMetabolic endocrine-mediated perturbations
IVR6.3 mg/kg 6.3 mg/kgIncreased cholesterol levelsMetabolic endocrine-mediated perturbations
IVR11.33 mg/kg 11.33 mg/kgAffects steroidogenesisReproductive endocrine-mediated perturbations
IVR11.33 mg/kg 11.33 mg/kgIncreased cholesterol levelsMetabolic endocrine-mediated perturbations
IVR11.33 mg/kg 11.33 mg/kgDecreased cholesterol levelsMetabolic endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.